Meet the F&M Scientific Advisory Board

Forbes & Manhattan Pharma Portfolio Companies

Jungle Medicines

Jungle Medicines is a private company owned by Forbes & Manhattan. Jungle Medicines is focused on redefining mental health, addiction treatments and the restorative health and wellness market through the intersection of ancient plant-based wisdom with modern science.

 

 

 

Coca Leaf Pharma

Coca Leaf Pharma is a private biopharma company owned by Forbes & Manhattan. Coca Leaf Pharma is focused on developing medicinally-directed products derived from the coca plant. Coca Leaf Pharma has exclusive rights to conduct research in indigenous territories of South America through a formal partnership agreement to establish beneficial medicinal properties of the coca plant.

Forbes & Manhattan Scientific Advisory Board

Brian Fuerhlein MD, PhD

Associate Professor of Psychiatry, Yale University School of Medicine and Director, Psychiatric, Emergency Room 

 

New Treatments for opioid and other substance use disorders.

Christopher Hammond, MD, PhD

Director, the Johns Hopkins University Center for Adolescent Substance Abuse and Prevention 

 

Ground-breaking research in cannabis, substance use and brain development.

Christopher McCurdy Ph.D, B.S. Ph., FAAPS

Professor, Medicinal Chemistry at college of Pharmacy University of Florida 

Christopher is a broadly trained medicinal chemist, focused on herbal treatment for substance use disorders.

David Baron DO, MEd

Provost and SVP Western University of Health Sciences, and 2018 Fulbright Distinguished Chair in Brain Science. 

Former Olympic athlete expertise in nutrition, sports performance, and enhancement.

Elliot Richelson, M.D.

Emeritus Donald and Lucy Dayton Professor in the Department of Psychiatry and Psychology and Department of Pharmacology at Mayo Foundation for Medical Education and Research and Chief Medical Officer for Refresh Mental Health

New psychopharmacological treatment discovery for ADD, depression, anxiety, and pain.

Jean Lud Cadet, M.D.

Chief, Molecular Neuropsychiatry Research Branch National Institute of Drug Abuse, National Institutes of Health 

Pioneering researcher on cocaine, methamphetamine, and brain injury.

Jonelle Toothman

Jonelle is the Co-founder and CEO of NextGen Biologics, Inc

Regenerative medicine, skin and wound care.

Josh Siegel, MD, PhD

Washington University School of Medicine and Psychedelic researcher

Institute of clinical and translational sciences focused on psilocybin, ketamine, and nitrous oxide.

Kevin Hill, M.D.

Co-Chair - Director, Division of Addiction Psychiatry, Associate Professor of Psychiatry at BIDMC/Harvard Medical School 

Dr. Kevin is focused on pain, performance and substance use disorders treatment innovations.

Mark Gold MD

Chief Scientific Officer – Forbes & Manhattan Pharma

Washington University in St Louis.

Nicole Avena, PhD.

Co-Chair

PhD Mt. Sinai School of Medicine and Princeton University Research neuroscientist and a pioneer in the field of food addiction.

Paul Carney, MD

Chairman and Pediatric Neurology at U.F. and UNC. 

Currently, Professor, Pediatric Neurology, University of Missouri, CBD and Cannabis for developmental & seizure disorders.

Rajendra Badgaiyan MD

Chief of Psychiatry at South Texas Veterans Health Care System San Antonio, Texas, Professor of Psychiatry at Long School of Medicine University of Texas Health Psychiatric authority on brain imaging and consciousness

Psychiatric authority on brain imaging and consciousness.

Steven Stanos, D.O.

Medical Director of Swedish Health System Pain Medicine and Services in Seattle, Washington

Improving treatment of pain in primary care and in specialty pain medicine clinics.

Vaughn McCall, MD

Case Distinguished University Chair of the Department of Psychiatry and Health Behavior at the Medical College of Georgia (MCG) at Augusta University and Executive Vice Dean of MCG 

New psychopharmacological treatment discovery for sleep disorders and getting the most benefit from sleep.